Immune Checkpoint Inhibitors and Uveitis: Understanding the Risks and Management
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, offering new hope to patients by enabling the body’s own immune system to fight tumors. However, this systemic activation can sometimes lead to “immune-related adverse dysregulation,” where the immune system attacks healthy organs. One such complication is uveitis—an inflammation of the uvea, the middle layer of the eye.
Recent data presented by Dr. Charlie Zhang at the Retina World Congress (May 14-17, 2026) highlights a shift in the landscape of cancer-related eye complications. While uveitis was once considered an uncommon side effect, its prevalence is rising as ICIs become a standard of care for more patients.
- Patients with melanoma face a 2.47 times higher risk of developing uveitis.
- Combination therapy (PD-1 and CTLA-4) significantly increases risk (4.92 times higher) compared to monotherapy.
- Treatment management is determined by severity grading, ranging from continuing therapy with topical steroids to complete cessation of ICIs.
Who is Most at Risk?
Not all patients on ICI therapy are equally susceptible to ocular inflammation. An analysis of 157,493 patients on ICI therapy identified specific risk factors that clinicians must monitor.
High-Risk Groups
- Melanoma Patients: Those being treated for melanoma have a 2.47-times higher risk of developing uveitis.
- Combination Therapy: Patients receiving a combination of PD-1 and CTLA-4 inhibitors are at a much higher risk—4.92 times higher—than those receiving monotherapy.
Lower-Risk Groups
Interestingly, the data suggests that age may play a protective role, as older patients demonstrated a lower risk (HR = 0.977) of developing the condition.
Recognizing the Signs of ICI-Uveitis
Diagnosing ICI-associated uveitis can be challenging because there are no “pathognomonic” findings—meaning there isn’t one single sign that definitively proves the diagnosis. According to Dr. Zhang, the clinical presentation is highly variable.
Timing and Type: In most instances, uveitis appears 8 to 9 weeks after the start of therapy. The condition typically manifests in one of three ways, split roughly equally among patients:
- Anterior Uveitis: Inflammation in the front of the eye.
- Posterior Uveitis: Inflammation in the back of the eye.
- Panuveitis: Inflammation affecting the entire uveal tract.
It’s critical for clinicians to perform a full evaluation to rule out infectious causes or “masqueraders.” For example, metastatic melanoma of the retina or vitreous can mimic the appearance of ICI-induced uveitis, making a precise diagnosis essential for correct treatment.
Management and Treatment Guidelines
Management of ICI-associated uveitis follows severity grading guidelines provided by the American Society of Clinical Oncology (ASCO). The goal is to balance the need for cancer treatment with the need to preserve vision.
| Severity Grade | Clinical Definition | Management Strategy |
|---|---|---|
| Grade 1 | Mild anterior disease | Continue ICI therapy; use topical steroids and lubricants. |
| Grade 2 | Moderate disease | Temporarily hold ICI; use topical steroids and a cycloplegic. Oral steroids may be considered. ICI resumes only after resolution. |
| Grade 3 & 4 | Severe disease | Oral prednisone, IV methylprednisolone, or local steroid injections. Grade 4 typically requires permanent cessation of ICI. |
Because these treatments involve complex trade-offs, Dr. Zhang emphasizes that treatment must begin with a direct discussion with the patient’s oncology team. If the priority is to maintain the ICI therapy to fight the cancer, clinicians should employ a progressive approach using local and systemic corticosteroids.
Looking Ahead
As the use of immune checkpoint inhibitors continues to expand, the intersection of oncology and ophthalmology becomes increasingly vital. Early detection of uveitis—particularly in high-risk melanoma patients and those on combination therapies—can prevent permanent vision loss while allowing patients to continue their life-saving cancer treatments.